Initial Statement of Beneficial Ownership (Form 3)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * He Wei-Wu 2. Date of Event Requiring Statement (Month/Day/Year) 03/18/2026 3. Issuer Name and Ticker or Trading Symbol CASI Pharmaceuticals, Inc. [CASIF] (Last) (First) (Middle) 1701-1702, CHINA CENTRAL OFFICE TOWER 1,, NO. 81 JIANGUO ROAD CHAOYANG DISTRICT 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) 5. If Amendment, Date Original Filed (Month/Day/Year) (Street) BEIJING 100025 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Ordinary Share 1,910,550 D Ordinary Share 44,107 I See Footnote(1) Ordinary Share 753,234 I See Footnote(2) Ordinary Share 300,000 I See Footnote(3) Ordinary Share 100,000 I See Footnote(4) Ordinary Share 637,644 I See Footnote(5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Convertible Note (right to convert)	03/28/2026	12/26/2028	Ordinary Share	(6)	(6)	I	See Footnote(7)
Convertible Note (right to convert)	04/10/2026	01/08/2029	Ordinary Share	(6)	(6)	I	See Footnote(7)
Convertible Note (right to convert)	05/21/2026	02/18/2029	Ordinary Share	(6)	(6)	I	See Footnote(7)
Option (right to buy)	05/12/2025	05/12/2033	Ordinary Share	20,000	$1.93	D
Option (right to buy)	05/12/2026	05/12/2033	Ordinary Share	20,000	$1.93	D
Option (right to buy)	04/14/2023	04/27/2031	Ordinary Share	100,000	$1.93	D
Option (right to buy)	04/27/2025	04/27/2031	Ordinary Share	100,000	$1.93	D
Option (right to buy)	(8)	04/27/2031	Ordinary Share	300,000	$1.93	D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
He Wei-Wu 1701-1702, CHINA CENTRAL OFFICE TOWER 1, NO. 81 JIANGUO ROAD CHAOYANG DISTRICT BEIJING 100025	X	X

Signatures

/s/ Wei-Wu He		03/18/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Held by Emerging Technology Partners, LLC, a Delaware limited liability company, of which Dr. He is founder and managing partner.
(2)	Held by ETP Global Fund. L.P., a Delaware limited partnership, of which Emerging Technology Partners, LLC is the general partner.
(3)	Held by ETP BioHealth III Fund, L.P., a Delaware limited partnership, of which Emerging Technology Partners, LLC is the general partner.
(4)	Held by HE Family GRAT, a grantor retained annuity trust organized under the law of Nevada for the benefit of Dr. Wei-Wu He's family members, and Dr. Wei-Wu He is the trustee of HE Family GRAT.
(5)	Held by Huiying Memorial Foundation, a 501(c)(3) private family foundation under the law of Delaware and Dr. He is a member of the board of trustees and an officer of the Huiying Memorial Foundation. Dr. He does not participate in the investment decisions of the Foundation with respect to CASI's ordinary shares and disclaims beneficial ownership of CASI's ordinary shares held by Huiying Memorial Foundation.
(6)	The conversion price is volume weighted average closing price of the issuer's Ordinary Shares during the five consecutive trading days immediately preceding the date of conversion notice by ETP Global Fund III L.P. In no event shall the conversion price be higher than US $2 per Ordinary Share or lower than US $1 per Ordinary Share. Pursuant to the trading price of the issuer's ordinary shares as of March 17, 2026, the amount of ordinary shares convertible under each Note is 5,000,000 (without considering accrued but unpaid interest).
(7)	Held by ETP Global Fund III L.P., , a Delaware limited partnership, of which Emerging Technology Partners, LLC is the general partner.
(8)	Performance based options granted and exercisable upon achievement.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.